

Intranasal Corticosteroids Drug Use Criteria

Created: 6/9/10

Revised: 9/23/15, 5/21/17, 5/28/21, 3/25/24

Includes:

Beconase AQ®, QNasal®	<i>Beclomethasone</i>
Rhinocort®, Rhinocort Allergy®	<i>Budesonide</i>
Omnaris®, Zetonna®	<i>Ciclesonide</i>
Nasalide®, Nasarel®	<i>Flunisolide</i>
Veramyst®	<i>Fluticasone furoate</i>
Nasonex®	<i>Mometasone</i>
Nasacort®, Nasacort Allergy 24HR®	Triamcinolone

*Highlighted in yellow is preferred agent after fluticasone propionate (Flonase®)

**Generic fluticasone propionate nasal spray is a covered benefit without a prior authorization (16 gram only). Nasacort Allergy 24HR® (triamcinolone) may be considered as a second line agent for those patients unable to tolerate generic fluticasone nasal spray and meeting the below drug use criteria.*

Guideline for Use:

1. Has there been a trial and failure or contraindication for preferred fluticasone propionate 16 gram?
 - a. If yes, go to 2
 - b. If no, deny as not meeting criteria. Trial/failure or contraindication of fluticasone propionate is required.
2. Is the member 20 years of age or younger?
 - a. If yes, go to 6
 - b. If no, go to 3
3. Is the patient being treated for an above the line diagnosis for which a substantial body of evidence exists to support use of intranasal corticosteroids?
 - a. If yes, continue to 4
 - b. If no, deny as below the line
4. Does the patient have a funded condition such as chronic sinusitis, acute sinusitis, or sleep apnea for which a substantial body of evidence exists to support use of intranasal corticosteroids?
 - a. If yes, go to 6
 - b. If no, go to 5

**Please note there is insufficient evidence supporting use of intranasal corticosteroids for COPD.*

Approved by WOAHP&T on 5/22/2017

Approved by Advanced Health Pharmacy and Therapeutics Committee 4/22/2019, 6/9/2021

5. Does the patient have a diagnosis of asthma or reactive airway disease, or a covered comorbid condition?
 - a. If yes, go to 6
 - b. If no, deny as not meeting criteria. Off-label use of medication is not a covered benefit of the Oregon Health Plan.
6. Is there a clinical rationale for use of a nonformulary agent (e.g. documented intolerance to formulary agent, etc.)?
 - a. If yes and request is for Nasacort Allergy 24HR®, approve for the requested duration of therapy up to 6 months
 - b. If yes and request is for nonformulary agent, and documented failure or intolerance to both fluticasone propionate and Nasacort Allergy 24HR® has been substantiated in the chart note and prescription fill history, review price comparison of intranasal steroids and recommend use of next least costly option. If next least costly alternative prescribed, approve for 6 months. Otherwise deny as not meeting criteria; does not meet the least costly alternative rule for OHP

Rationale: To promote the use of intranasal corticosteroids for conditions funded for coverage by Oregon Health Plan and where there is evidence of benefit. Treatment for allergic or non-allergic rhinitis is only funded for coverage when it exacerbates asthma, sinusitis, or obstructive sleep apnea. Evidence is insufficient to draw any conclusions about comparative effectiveness, efficacy, or safety between intranasal corticosteroid formulations for management of asthma-related outcomes, obstructive sleep apnea, acute sinusitis and chronic rhinosinusitis, therefore the least costly formulations will be covered. Also, to align coverage with the State FFS drug use criteria for intranasal corticosteroids.

FDA Approved Indication: <i>Generic Name (Brand Name)</i>	FDA Approved Indications
<i>Beclomethasone (Beconase AQ®)</i>	Allergic, non-allergic rhinitis ≥ 6yo
<i>Beclomethasone (QNASL®)</i>	Allergic rhinitis ≥ 4 yo
<i>Budesonide (Rhinocort Aqua, Rhinocort Allergy)</i>	Allergic rhinitis ≥ 6 yo
<i>Ciclesonide (Omnaris)</i>	Allergic rhinitis ≥ 12yo
<i>Ciclesonide (Zetonna)</i>	Allergic rhinitis ≥ 12 yo
<i>Flunisolide</i>	Allergic rhinitis ≥ 6 yo
<i>Fluticasone furoate (Veramyst)</i>	Allergic rhinitis ≥ 2 yo
<i>Fluticasone propionate (Flonase, Flonase Allergy Relief)</i>	Allergic rhinitis ≥ 4yo
<i>Mometasone (Nasonex)</i>	Allergic rhinitis ≥ 2yo, Nasal polyps ≥ 18yo
<i>Triamcinolone (Nasacort AQ, Nasacort Allergy 24HR)</i>	Allergic rhinitis ≥ 2 yo

References:

1. Drug Class Update: Nasal Allergy Inhalers. Oregon State University Drug Use Research and Management Program. August 2022.
https://www.orpd.org/durm/meetings/meetingdocs/2022_08_04/archives/2022_08_04_NasalAllergyInhalers_ClassUpdate.pdf
2. Intranasal Allergy Drug Class Review. Oregon State University Drug Use Research and Management Program. July 2015.

Approved by WOAHP P&T on 5/22/2017

Approved by Advanced Health Pharmacy and Therapeutics Committee 4/22/2019, 6/9/2021

http://www.orpdl.org/durm/meetings/meetingdocs/2015_07_30/archives/2015_07_30_IntranasalAllergyDrugsClassReview_FINAL.pdf

3. Advanced Health Drug Use Criteria. Last updated 09/23/2015.
4. Beconase AQ© Prescribing Information. Revised 2/2021
5. QNASL© Prescribing Information. Revised 3/2018
6. Rhinocort Aqua© Prescribing Information. Revised 12/2010
7. Omnaris© Prescribing Information. Revised 10/2019
8. Zetonna© Prescribing Information. Revised 1/2012
9. Veramyst© Prescribing Information. Revised 4/2007
10. Flonase© Prescribing Information. Revised 1/2015
11. Nasonex© Prescribing Information. Revised 1/2011
12. Nasacort AQ© Prescribing Information. Revised 2008
13. Oregon Administrative Rule 410-120-1200 (3)(g)(m)
14. Oregon Administrative Rule 410-141-3825 (1)(b)(c)

Approved by WOAHP&T on 5/22/2017

Approved by Advanced Health Pharmacy and Therapeutics Committee 4/22/2019, 6/9/2021